FY2026 EPS Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Increased by HC Wainwright

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research report issued on Friday, November 3rd. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $6.40 for the year, up from their prior estimate of $6.28. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ FY2027 earnings at $9.70 EPS.

MIRM has been the subject of a number of other reports. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $35.00 to $38.00 in a research note on Tuesday, October 3rd. Raymond James decreased their price target on Mirum Pharmaceuticals from $84.00 to $77.00 and set a “strong-buy” rating for the company in a research note on Wednesday, October 18th. Evercore ISI restated an “outperform” rating and issued a $62.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, October 17th. Cantor Fitzgerald assumed coverage on Mirum Pharmaceuticals in a research note on Tuesday, October 24th. They set an “overweight” rating and a $50.00 target price for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 18th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $51.11.

Mirum Pharmaceuticals Stock Up 5.7 %

MIRM stock opened at $30.00 on Monday. The company has a quick ratio of 6.44, a current ratio of 6.59 and a debt-to-equity ratio of 3.89. The business has a 50 day moving average price of $29.16 and a two-hundred day moving average price of $27.42. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -6.98 and a beta of 1.20. Mirum Pharmaceuticals has a twelve month low of $17.49 and a twelve month high of $33.39.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.11). The company had revenue of $37.50 million during the quarter, compared to the consensus estimate of $30.00 million. Mirum Pharmaceuticals had a negative net margin of 152.27% and a negative return on equity of 103.59%.

Insider Activity at Mirum Pharmaceuticals

In other news, Director Patrick J. Heron purchased 147,991 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average cost of $26.25 per share, for a total transaction of $3,884,763.75. Following the purchase, the director now directly owns 147,991 shares of the company’s stock, valued at approximately $3,884,763.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Patrick J. Heron purchased 147,991 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average cost of $26.25 per share, for a total transaction of $3,884,763.75. Following the purchase, the director now directly owns 147,991 shares of the company’s stock, valued at approximately $3,884,763.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jolanda Howe sold 3,459 shares of the business’s stock in a transaction on Friday, August 25th. The shares were sold at an average price of $26.23, for a total value of $90,729.57. The disclosure for this sale can be found here. Insiders bought 162,678 shares of company stock worth $4,323,280 in the last ninety days. 24.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Silverarc Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Silverarc Capital Management LLC now owns 106,375 shares of the company’s stock valued at $2,752,000 after acquiring an additional 436 shares in the last quarter. Metropolitan Life Insurance Co NY raised its holdings in Mirum Pharmaceuticals by 49.7% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,464 shares of the company’s stock valued at $38,000 after acquiring an additional 486 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 98.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock valued at $31,000 after acquiring an additional 488 shares in the last quarter. Royal Bank of Canada raised its holdings in Mirum Pharmaceuticals by 40.1% in the 2nd quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock valued at $48,000 after acquiring an additional 530 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 4.9% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,037 shares of the company’s stock valued at $358,000 after acquiring an additional 654 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.